Loading...

James Allison, MD

Title(s)NON-SENATE ACAD EMERITUS(WOS), Medicine
SchoolSchool of Medicine
Address1001 Potrero Ave
San Francisco CA 94110
Phone510-891-3250
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Pennsylvania, Philadelphia, PAAB05/1964French
    University of Rochester, Rochester, NYMD05/1969Medicine
    UCLA, Los Angeles, CAPGY 1&205/1971Internal Medicine
    UCSF, San Francisco, CAPGY 3 and Fellowship in Gastroenterology06/1974Internal Medicine/Gastroenterology
    Collapse Awards and Honors
    Kaiser Oakland Medical Center1996Lowell Beal MD Award
    Bay Area Chapter Crohn's and Colitis Foundation2003Crohn’s and Colitis Foundation’s Premier Physician Award
    American Gastroenterological Association (AGA)2004Distinguished Clinician Award
    American Cancer Society20172017 Achievement Award

    Collapse Overview 
    Collapse Overview
    Dr. Allison received a BA with honors from the University of Pennsylvania, and, in 1969, his MD from the University of Rochester. His entire post graduate training was at the University of California Los Angeles (UCLA) and the University of California San Francisco (UCSF). He began his medical career at Kaiser San Rafael in 1974 where he was that groups’ first gastroenterologist. In 1977 he transferred to Kaiser Oakland Medical Center where he was a full-time gastroenterologist and educator (Assistant Program Director – Internal Medicine) and where he devoted the majority of his time to patient care, administration, clinical research and teaching. In 1996 he received the Lowell Beal MD Award “in appreciation of his example of academic excellence combined with warm humanity.” He retired as a clinician from Kaiser in 1998.

    After his retirement from Kaiser, Dr. Allison was invited to be a member of the University of California San Francisco (UCSF) faculty and an Emeritus Investigator at Kaiser Permanente’s Division of Research.

    He is Clinical Professor of Medicine Emeritus at UCSF and is a member of the Division of Gastroenterology at UCSF and the San Francisco General Hospital. In 2003, he received the Bay Area Chapter of the Crohn’s and Colitis Foundation’s Premier Physician Award, and in 2004, the American Gastroenterological Association‘s (AGA) Distinguished Clinician Award. He is a fellow of the American College of Physicians and of the American Gastroenterological Association.

    Dr. Allison is a national and international expert on screening tests for colon cancer. In a publication in The New England Journal of Medicine in 1996, he was the first person in the U.S. to show that the fecal immunochemical test (FIT) was superior to the standard guaiac fecal occult blood test for screening for colorectal cancer. Since 2000 Dr. Allison has been an ad hoc consultant to the Centers for Disease Control, National Cancer Institute and the Agency for Healthcare Research and Quality (AHRQ) on issues concerned with screening for colorectal cancer. Currently he is working with the California Colorectal Cancer Coalition (C4), California and San Francisco Departments of Public Health to increase screening rates in the uninsured/underserved population by instituting a FIT based screening program in clinics served by safety net hospitals. The screening model this group has developed is being exported to other parts of the San Francisco Bay Area and state of California and has support from both the CDC and the American Gastroenterological Association.

    In addition to expertise in colorectal cancer screening tests, Dr. Allison has been a dedicated researcher in inflammatory bowel disease (IBD). In 2005 he helped establish an Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) registry of over 25000 patients at Kaiser’s Division of Research. In the past 7 years, close to 20 peer reviewed publications have been published from information contained in the registry.

    Dr. Allison’s screening and IBD research has been published in the Annals of Internal Medicine, The New England Journal of Medicine, Gastroenterology, Clinical Gastroenterology and Hepatology, the Journal of the National Cancer Institute and other peer reviewed journals. He has been quoted in Prevention Magazine, the Ladies’ Home Journal, the Wall Street Journal, the San Francisco Chronicle and the New York Times.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. PMID: 31400961.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    2. Why What You May Not Know About Fecal Immunochemical Testing Matters. Ann Intern Med. 2019 07 16; 171(2):151-152. Allison J. PMID: 31307085.
      View in: PubMed   Mentions:    Fields:    
    3. Why What You May Not Know About Fecal Immunochemical Testing Matters. Ann Intern Med. 2019 03 05; 170(5):342-343. Allison J. PMID: 30802903.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Potential Intended and Unintended Consequences of Recommending Initiation of Colorectal Cancer Screening at Age 45 Years. Gastroenterology. 2018 10; 155(4):950-954. Liang PS, Allison J, Ladabaum U, Martinez ME, Murphy CC, Schoen RE, Shaukat A, Tinmouth J, Gupta S. PMID: 30138614.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    5. Yield of Colonoscopy After a Positive Result From a Fecal Immunochemical Test OC-Light. Clin Gastroenterol Hepatol. 2018 10; 16(10):1593-1597.e1. Alsayid M, Singh MH, Issaka R, Laleau V, Day L, Lee J, Allison J, Somsouk M. PMID: 29660528.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. PMID: 29361468.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    7. Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design. Am J Gastroenterol. 2017 Nov; 112(11):1736-1746. Dominitz JA, Robertson DJ, Ahnen DJ, Allison JE, Antonelli M, Boardman KD, Ciarleglio M, Del Curto BJ, Huang GD, Imperiale TF, Larson MF, Lieberman D, O'Connor T, O'Leary TJ, Peduzzi P, Provenzale D, Shaukat A, Sultan S, Voorhees A, Wallace R, Guarino PD. PMID: 29016565.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    8. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting. Clin Gastroenterol Hepatol. 2017 Aug; 15(8):1265-1270.e1. Akram A, Juang D, Bustamante R, Liu L, Earles A, Ho SB, Wang-Rodriguez J, Allison JE, Gupta S. PMID: 28167157.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer. Cancer. 2016 Mar 15; 122(6):826-39. Young GP, Senore C, Mandel JS, Allison JE, Atkin WS, Benamouzig R, Bossuyt PM, Silva MD, Guittet L, Halloran SP, Haug U, Hoff G, Itzkowitz SH, Leja M, Levin B, Meijer GA, O'Morain CA, Parry S, Rabeneck L, Rozen P, Saito H, Schoen RE, Seaman HE, Steele RJ, Sung JJ, Winawer SJ. PMID: 26828588.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    10. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut. 2015 Aug; 64(8):1327-37. Tinmouth J, Lansdorp-Vogelaar I, Allison JE. PMID: 26041750.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansPHPublic Health
    11. Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist. Eur J Cancer Prev. 2015 Jan; 24(1):24-6. Fraser CG, Allison JE, Young GP, Halloran SP, Seaman HE. PMID: 24584197.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    12. Advances in Fecal Occult Blood Tests: the FIT revolution. Dig Dis Sci. 2015 Mar; 60(3):609-22. Young GP, Symonds EL, Allison JE, Cole SR, Fraser CG, Halloran SP, Kuipers EJ, Seaman HE. PMID: 25492500.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansPHPublic Health
    13. Navigating the murky waters of colorectal cancer screening and health reform. Am J Public Health. 2014 Jun; 104(6):982-6. Green BB, Coronado GD, Devoe JE, Allison J. PMID: 24825195.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    14. Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst. 2014 Apr; 106(4):dju032. Gupta S, Sussman DA, Doubeni CA, Anderson DS, Day L, Deshpande AR, Elmunzer BJ, Laiyemo AO, Mendez J, Somsouk M, Allison J, Bhuket T, Geng Z, Green BB, Itzkowitz SH, Martinez ME. PMID: 24681602.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansPHPublic Health
    15. Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver. 2014 Mar; 8(2):117-30. Allison JE, Fraser CG, Halloran SP, Young GP. PMID: 24672652.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansPHPublic Health
    16. A standard for Faecal Immunochemical TesTs for haemoglobin evaluation reporting (FITTER). Ann Clin Biochem. 2014 Mar; 51(Pt 2):301-2. Fraser CG, Allison JE, Young GP, Halloran SP, Seaman H. PMID: 24345727.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    17. FIT testing: an overview. Curr Gastroenterol Rep. 2013 Nov; 15(11):357. Day LW, Bhuket T, Allison J. PMID: 24218070.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    18. Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT). Clin Chem Lab Med. 2013 Nov; 51(11):2065-7. Fraser CG, Halloran SP, Allison JE, Young GP. PMID: 23787468.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    19. Racial and ethnic differences in health care utilization and outcomes among ulcerative colitis patients in an integrated health-care organization. Dig Dis Sci. 2014 Feb; 59(2):287-94. Li D, Collins B, Velayos FS, Liu L, Lewis JD, Allison JE, Flowers NT, Hutfless S, Abramson O, Herrinton LJ. PMID: 24173809.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    20. Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening. Clin Gastroenterol Hepatol. 2013 Jul; 11(7):839-40. Fraser CG, Allison JE, Young GP, Halloran SP. PMID: 23591278.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    21. Measurement of colorectal cancer test use with medical claims data in a safety-net health system. Am J Med Sci. 2013 Feb; 345(2):99-103. Gupta S, Tong L, Anderson P, Rose B, Carter E, Koch M, Argenbright K, Ahn C, Allison J, Skinner CS. PMID: 22814361.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    22. Colorectal-cancer screening. N Engl J Med. 2012 05 31; 366(22):2130; author reply 1231. Allison JE. PMID: 22646640.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012 Aug; 143(2):382-9. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. PMID: 22609382.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    24. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst. 2012 Jun 06; 104(11):810-4. Fraser CG, Allison JE, Halloran SP, Young GP. PMID: 22472305.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    25. Newer fecal tests: opportunities for professionals in laboratory medicine. Clin Chem. 2012 Jun; 58(6):963-5. Fraser CG, Allison JE, Young GP, Halloran SP. PMID: 22452971.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    26. Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology. 2012 Mar; 142(3):422-4. Allison JE, Fraser CG, Halloran SP, Young GP. PMID: 22281273.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    27. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011 Dec; 106(12):2146-53. Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. PMID: 22031357.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    28. ACP Journal Club. Fecal immunochemical tests had better sensitivity for detecting colorectal neoplasia in aspirin users than in nonusers. Ann Intern Med. 2011 Apr 19; 154(8):JC4-10. Allison JE, Fraser CG. PMID: 21502636.
      View in: PubMed   Mentions:    Fields:    
    29. FIT: a valuable but underutilized screening test for colorectal cancer-it's time for a change. Am J Gastroenterol. 2010 Sep; 105(9):2026-8. Allison JE. PMID: 20818351.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    30. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology. 2010 Nov; 139(5):1511-8. Velayos FS, Liu L, Lewis JD, Allison JE, Flowers N, Hutfless S, Abramson O, Perry GS, Herrinton LJ. PMID: 20659470.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic Health
    31. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. J Pediatr. 2010 Aug; 157(2):233-239.e1. Abramson O, Durant M, Mow W, Finley A, Kodali P, Wong A, Tavares V, McCroskey E, Liu L, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Perry GS, Cannon R, Herrinton LJ. PMID: 20400099.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    32. Colorectal cancer screening guidelines: the importance of evidence and transparency. Gastroenterology. 2010 May; 138(5):1648-1652.e2. Allison JE. PMID: 20211181.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    33. The best screening test for colorectal cancer is the one that gets done well. Gastrointest Endosc. 2010 Feb; 71(2):342-5. Allison JE. PMID: 20152313.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    34. Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization. Pharmacoepidemiol Drug Saf. 2009 Nov; 18(11):1086-93. Liu L, Allison JE, Herrinton LJ. PMID: 19672855.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    35. New screening guidelines for colorectal cancer: a practical guide for the primary care physician. Prim Care. 2009 Sep; 36(3):575-602. Allison JE, Potter MB. PMID: 19616156.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    36. Screening for colorectal cancer in a safety-net health care system: access to care is critical and has implications for screening policy. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2373-9. Gupta S, Tong L, Allison JE, Carter E, Koch M, Rockey DC, Anderson P, Ahn C, Argenbright K, Skinner CS. PMID: 19745221.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    37. The imperative of equal funding for studies that evaluate any of the evidence-based, guideline-recommended colorectal cancer screening tests. Clin Gastroenterol Hepatol. 2009 Dec; 7(12):1269-71. Allison JE. PMID: 19695347.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology. 2009 Aug; 137(2):502-11. Herrinton LJ, Liu L, Fireman B, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Abramson O, Altschuler A, Perry GS. PMID: 19445944.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    39. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008 Oct 07; 149(7):441-50, W81. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL. PMID: 18838724.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCTClinical Trials
    40. Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol. 2008 Sep; 6(9):999-1003. Allison J, Herrinton LJ, Liu L, Yu J, Lowder J. PMID: 18774533.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    41. Patterns of infliximab use among Crohn's disease patients in a community setting. Inflamm Bowel Dis. 2008 Sep; 14(9):1265-72. Pressman AR, Hutfless S, Velayos F, Fireman B, Lewis JD, Allison J, Abramson O, Herrinton LJ. PMID: 18452199.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    42. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008 Aug; 103(8):1998-2006. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. PMID: 18796097.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    43. Gastroenterologists' attitudes and self-reported practices regarding inflammatory bowel disease. Inflamm Bowel Dis. 2008 Jul; 14(7):992-9. Altschuler A, Collins B, Lewis JD, Velayos F, Allison JE, Hutfless S, Liu L, Herrinton LJ. PMID: 18300277.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    44. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology. 2007 Dec; 133(6):1779-86. Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ. PMID: 18054550.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    45. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007 Oct 03; 99(19):1462-70. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV. PMID: 17895475.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansPHPublic Health
    46. Should recommendations for colorectal-cancer screening be changed? Nat Clin Pract Oncol. 2007 Jul; 4(7):392-3. Allison JE. PMID: 17519918.
      View in: PubMed   Mentions:    Fields:    
    47. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. Am J Gastroenterol. 2007 Jul; 102(7):1429-35. Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. PMID: 17437504.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    48. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis. 2007 Apr; 13(4):451-61. Herrinton LJ, Liu L, Lafata JE, Allison JE, Andrade SE, Korner EJ, Chan KA, Platt R, Hiatt D, O'Connor S. PMID: 17219403.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    49. Screening tests for colorectal cancer: a menu of options remains relevant. Curr Oncol Rep. 2006 Nov; 8(6):492-8. Allison JE, Lawson M. PMID: 17040627.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    50. Colon Cancer Screening Guidelines 2005: the fecal occult blood test option has become a better FIT. Gastroenterology. 2005 Aug; 129(2):745-8. Allison JE. PMID: 16083728.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    51. Immunochemical fecal occult blood tests for colorectal cancer screening. Am J Med. 2004 Apr 01; 116(7):498; author reply 498-9. Allison JE. PMID: 15047043.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    52. A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease. Arch Intern Med. 2003 May 26; 163(10):1165-71. Allison JE, Hurley LB, Hiatt RA, Levin TR, Ackerson LM, Lieu TA. PMID: 12767952.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    James's Networks
    Concepts (208)
    Derived automatically from this person's publications.
    _
    Co-Authors (12)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _